Exagen (XGN) Aandelenoverzicht
Exagen Inc. ontwerpt, ontwikkelt en verkoopt verschillende testproducten onder de merknaam AVISE in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
XGN Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Exagen Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$7.43 |
| 52 Week Hoogtepunt | US$12.23 |
| 52 Week Laag | US$2.59 |
| Bèta | 2.03 |
| 1 maand verandering | 58.76% |
| 3 maanden verandering | 74.00% |
| 1 Jaar Verandering | -24.49% |
| 3 jaar verandering | 187.73% |
| 5 jaar verandering | -44.76% |
| Verandering sinds IPO | -60.01% |
Recent nieuws en updates
Narratiefupdate • Aug 19
XGN: Autoimmune Test Penetration And Peer Multiples Will Shape Future Upside
Exagen's analyst price target has shifted from $8 to $12 as analysts point to higher estimates, peer multiple moves and the company's biomarker testing track record to support a higher fair value range and updated assumptions around growth, margins and future P/E. Analyst Commentary Recent research on Exagen highlights a mix of optimism about the company’s autoimmune testing portfolio and caution around how that story translates into valuation and execution over time.Analyse-artikel • Aug 07
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results
Exagen Inc. ( NASDAQ:XGN ) just released its latest quarterly results and things are looking bullish. Exagen...Seeking Alpha • Aug 05
Exagen: The Path To Profitability Just Became More Credible
Summary Exagen delivered a standout quarter, with 16% revenue growth, record ASP, and near-breakeven adjusted EBITDA, reinforcing the turnaround thesis. XGN raised full-year revenue guidance to $72-75M, with Pharma Services revenue tripling and backlog growing, highlighting new long-term growth levers. Operating margin improved to -8.6%, and Q2 cash generation turned positive, signaling tangible progress toward profitability and improved liquidity. Despite a 38% post-earnings rally, I maintain a Buy rating, targeting 62% upside by 2028 as the business' fundamental improvements gain market recognition. Read the full article on Seeking Alpha
Narratiefupdate • Aug 05
XGN: Autoimmune Test Adoption And 2026 Guidance Will Support Future Upside
Analysts have lifted their price target on Exagen to about $9.71 from roughly $8.67, reflecting updated assumptions around revenue growth, margins and future P/E as they weigh recent coverage highlighting the company's autoimmune testing portfolio and its runway for further market penetration. Analyst Commentary Recent research coverage on Exagen highlights a mix of optimism around its autoimmune testing portfolio and some caution on execution and valuation.Recent updates
Narratiefupdate • Aug 19
XGN: Autoimmune Test Penetration And Peer Multiples Will Shape Future Upside
Exagen's analyst price target has shifted from $8 to $12 as analysts point to higher estimates, peer multiple moves and the company's biomarker testing track record to support a higher fair value range and updated assumptions around growth, margins and future P/E. Analyst Commentary Recent research on Exagen highlights a mix of optimism about the company’s autoimmune testing portfolio and caution around how that story translates into valuation and execution over time.Analyse-artikel • Aug 07
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results
Exagen Inc. ( NASDAQ:XGN ) just released its latest quarterly results and things are looking bullish. Exagen...Seeking Alpha • Aug 05
Exagen: The Path To Profitability Just Became More Credible
Summary Exagen delivered a standout quarter, with 16% revenue growth, record ASP, and near-breakeven adjusted EBITDA, reinforcing the turnaround thesis. XGN raised full-year revenue guidance to $72-75M, with Pharma Services revenue tripling and backlog growing, highlighting new long-term growth levers. Operating margin improved to -8.6%, and Q2 cash generation turned positive, signaling tangible progress toward profitability and improved liquidity. Despite a 38% post-earnings rally, I maintain a Buy rating, targeting 62% upside by 2028 as the business' fundamental improvements gain market recognition. Read the full article on Seeking AlphaNarratiefupdate • Aug 05
XGN: Autoimmune Test Adoption And 2026 Guidance Will Support Future Upside
Analysts have lifted their price target on Exagen to about $9.71 from roughly $8.67, reflecting updated assumptions around revenue growth, margins and future P/E as they weigh recent coverage highlighting the company's autoimmune testing portfolio and its runway for further market penetration. Analyst Commentary Recent research coverage on Exagen highlights a mix of optimism around its autoimmune testing portfolio and some caution on execution and valuation.
Narratiefupdate • Jul 16
XGN: Market Penetration Execution Will Shape Future Upside Potential
Exagen's analyst price target has been reset from $18.00 to $10.00, as analysts factor in a higher discount rate, more moderate revenue growth assumptions, and a sharply lower future P/E multiple, while still highlighting AVISE CTD's outperformance and early market penetration in recent research. Analyst Commentary Recent Street research on Exagen centers on how analysts weigh the company’s autoimmune testing portfolio, especially AVISE CTD, against the updated valuation framework reflected in the new price target.Narratiefupdate • Jul 02
XGN: Early Autoimmune Test Adoption Will Shape Execution-Driven Upside Potential
The analyst fair value estimate for Exagen has shifted from $12.00 to $8.00. The lower target is linked to updated assumptions on growth, profitability, and valuation multiples, while recent Street research highlights analysts' focus on the company's AVISE CTD testing performance and market penetration potential.Narratiefupdate • Jun 17
XGN: 2026 Guidance And Earnings Focus Will Support Stock Upside
Exagen's latest Narrative Update reflects a modest reduction in the analyst price target, with analysts pointing to slightly adjusted assumptions around discount rate, long term profit margin and future P/E as key drivers of the change in their dollar-denominated valuation framework. Analyst Commentary on Exagen Recent Street research on Exagen focuses on the trimmed price targets and the assumptions that sit behind those moves.Narratiefupdate • Jun 03
XGN: Volume Momentum And 2026 Guidance Are Expected To Support Upside
Analysts have trimmed their consolidated Exagen price target to $9, down $1 from the prior $10 level, citing softer realized pricing, slower near term gross margin expansion, and more cautious longer term revenue assumptions, while still maintaining generally constructive views on volume trends and reimbursement expertise. Analyst Commentary Recent research updates cluster around a common theme, with analysts trimming Exagen's price targets while still seeing room for execution on volume, reimbursement, and longer term profitability.Analyse-artikel • May 14
Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Exagen Inc. ( NASDAQ:XGN ) just released its first-quarter report and things are looking bullish. Revenues and losses...Narratiefupdate • Apr 24
XGN: Volume Strength And 2026 Guidance Should Support Future Share Gains
Narrative Update on Exagen Analysts have trimmed the average price target on Exagen by about $0.83 to reflect updated assumptions for slower revenue growth, softer profit margins, and more modest ASP and gross margin expansion in their models. Analyst Commentary Recent research shows analysts aligning around a more conservative view on Exagen, with several price targets reset to a tighter range as models are updated for softer pricing and margin assumptions.Narratiefupdate • Apr 10
XGN: Shares Should Rise As Volumes Offset Transitory Pricing Headwinds
Analysts have reduced their average 12 month price target on Exagen by a few dollars to around $9.50, citing lower than expected average selling prices as well as more conservative revenue and margin assumptions across recent research updates. Analyst Commentary Recent research updates point to a more cautious stance on Exagen, with several firms trimming their price targets while maintaining generally positive ratings on the shares.Narratiefupdate • Mar 26
XGN: Shares Should Rise As Volumes Support Long Term Margin Recovery
Analysts have reset expectations on Exagen, with several firms trimming their price targets to around $9 to $10. They cite lower than anticipated average selling prices, tempered revenue growth assumptions, and more gradual gross margin expansion in their updated models.Narratiefupdate • Mar 12
XGN: Shares Should Rise As Solid Volumes Offset Near Term Pricing Headwinds
The analyst price target for Exagen has been revised from a fair value of $13.29 to $9.50. Analysts have updated their models to account for lower near-term average selling prices, more conservative revenue growth assumptions, and more modest margin expectations, although overall volume trends remain generally stable.Narratiefupdate • Feb 11
XGN: Shares Will Rise As 2025 Revenue Guidance Supports Bullish Outlook
Narrative Update on Exagen The updated analyst price target for Exagen has moved lower to about $13.29 from $14.71. This reflects analysts' recent cuts to formal targets in the diagnostics group and slightly more conservative assumptions on fair value, discount rate, revenue growth, profit margin and future P/E.Narratiefupdate • Jan 27
XGN: Shares Will Rise As 2025 Guidance And Sector Fundamentals Strengthen Outlook
Analysts trimmed their price target on Exagen to $13 from $18, citing updated sector views from recent Q4 previews, even as they continue to expect solid diagnostics group fundamentals and 2026 outlooks. Analyst Commentary Bullish Takeaways Bullish analysts view the updated US$13 price target as still supported by what they describe as solid fundamentals across the diagnostics group, which they see as relevant for Exagen's valuation framework.Analyse-artikel • Jan 14
Investors Don't See Light At End Of Exagen Inc.'s (NASDAQ:XGN) Tunnel And Push Stock Down 28%
Unfortunately for some shareholders, the Exagen Inc. ( NASDAQ:XGN ) share price has dived 28% in the last thirty days...Narratiefupdate • Jan 12
XGN: Shares Will Rise As 2025 Guidance Supports Profitability Milestone
The updated analyst price target for Exagen reflects a move to roughly $14.71 from about $15.43, as analysts weigh mixed signals from recent target changes and sector commentary around solid diagnostics fundamentals, alongside ongoing headwinds in life science tools. Analyst Commentary Recent research on Exagen points to a mixed but constructive view, with price targets adjusted both higher and lower as analysts rework their models around upcoming earnings and sector trends.Narratiefupdate • Dec 21
XGN: Shares Will Rise As Resilient Demand Supports 2025 Profitability Prospects
Analysts raised their price target on Exagen to $15.00 from $11.00, citing updated models ahead of Q3 results that account for resilient fundamentals despite ongoing headwinds in life science tools, including tariffs, funding uncertainty, and China related pressures. Analyst Commentary Bullish analysts view the higher price target as a reflection of Exagen's ability to execute against a difficult macro backdrop and to sustain growth despite sector wide pressures.Analyse-artikel • Dec 18
Is Exagen (NASDAQ:XGN) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narratiefupdate • Dec 07
XGN: Shares Will Rise As Autoimmune Test Adoption Drives 50% Upside Potential
Analysts have lifted their price target on Exagen to $15 from $11, citing a refreshed model that reflects confidence in the company’s autoimmune diagnostics platform and its flagship AVISE CTD test, despite ongoing macro headwinds in the life science tools sector. Analyst Commentary Bullish analysts point to Exagen’s specialized focus on autoimmune diagnostics and its AVISE CTD test as key drivers of potential upside, supporting the higher price target and Buy rating in spite of sector-wide pressures.Narratiefupdate • Nov 22
XGN: Shares Will Gain As Buy Ratings Signal 50% Upside Potential
Analysts have raised their price target for Exagen from $14.00 to $15.43. They cite improved revenue growth estimates and ongoing optimism for the company's diagnostic test portfolio, despite sector headwinds.Analyse-artikel • Nov 18
The Market Doesn't Like What It Sees From Exagen Inc.'s (NASDAQ:XGN) Revenues Yet As Shares Tumble 27%
Exagen Inc. ( NASDAQ:XGN ) shareholders won't be pleased to see that the share price has had a very rough month...Analyse-artikel • Nov 07
Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$14.43
It's been a sad week for Exagen Inc. ( NASDAQ:XGN ), who've watched their investment drop 12% to US$10.38 in the week...Narratiefupdate • Nov 06
XGN: Shares Set To Climb On Strong Buy Ratings And 50% Upside Potential
Analysts have raised their price target for Exagen, increasing it from approximately $13.14 to $14.00 per share. They cite improved profit margin forecasts and confidence in the company’s diagnostic offerings, despite ongoing sector challenges.Narratiefupdate • Oct 23
Analysts Boost Exagen Price Target Highlighting Growth Potential and Strong Diagnostic Portfolio
Analysts have raised their price target for Exagen from approximately $11.17 to $13.14. They cite confidence in the company’s diagnostic test portfolio and expectations for improved adoption and financial performance.Analyse-artikel • Aug 05
Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
NasdaqGM:XGN 1 Year Share Price vs Fair Value Explore Exagen's Fair Values from the Community and select yours Despite...Analyse-artikel • Aug 01
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results
It's been a pretty great week for Exagen Inc. ( NASDAQ:XGN ) shareholders, with its shares surging 16% to US$8.40 in...Analyse-artikel • May 18
Exagen Inc.'s (NASDAQ:XGN) Shares Bounce 34% But Its Business Still Trails The Industry
Exagen Inc. ( NASDAQ:XGN ) shares have continued their recent momentum with a 34% gain in the last month alone. The...Analyse-artikel • May 09
Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$7.75
As you might know, Exagen Inc. ( NASDAQ:XGN ) recently reported its quarterly numbers. It looks like a positive result...Seeking Alpha • Apr 26
Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability
Summary We initiate coverage on Exagen with a Buy rating, citing a promising turnaround with growing diagnostics, improved margins, and new biomarker tests for lupus and RA. Despite a rocky history, Exagen's recent momentum, modest valuation, and potential upside from new products make it an attractive long-term speculative buy. Financially, Exagen reported $55.6 million in 2024 revenue, improved margins, and expects positive adjusted EBITDA by Q4 2025, supported by new product launches. Key risks include reimbursement uncertainty, competition, cash burn, and execution challenges, but these are balanced by the stock's current valuation and growth potential. Read the full article on Seeking Alpha
Nieuw narratief • Apr 09
Biomarker Launch And AVISE CTD Expansion Will Drive Future Success
New biomarkers and biopharma partnerships are expected to drive revenue growth and enhance diagnostic capabilities, accelerating earnings growth.Analyse-artikel • Apr 03
There's No Escaping Exagen Inc.'s (NASDAQ:XGN) Muted Revenues Despite A 45% Share Price Rise
The Exagen Inc. ( NASDAQ:XGN ) share price has done very well over the last month, posting an excellent gain of 45...Analyse-artikel • Mar 04
Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyse-artikel • Feb 05
Exagen Inc. (NASDAQ:XGN) Surges 40% Yet Its Low P/S Is No Reason For Excitement
Exagen Inc. ( NASDAQ:XGN ) shares have continued their recent momentum with a 40% gain in the last month alone. The...Analyse-artikel • Dec 22
Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Despite an already strong run, Exagen Inc. ( NASDAQ:XGN ) shares have been powering on, with a gain of 26% in the last...Analyse-artikel • Sep 06
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified
Despite an already strong run, Exagen Inc. ( NASDAQ:XGN ) shares have been powering on, with a gain of 40% in the last...Analyse-artikel • Aug 07
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report
Exagen Inc. ( NASDAQ:XGN ) just released its quarterly report and things are looking bullish. The results overall were...Analyse-artikel • Jul 13
Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price
You may think that with a price-to-sales (or "P/S") ratio of 0.6x Exagen Inc. ( NASDAQ:XGN ) is definitely a stock...Analyse-artikel • May 21
Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyse-artikel • Mar 26
Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge
Exagen Inc. ( NASDAQ:XGN ) shareholders won't be pleased to see that the share price has had a very rough month...Analyse-artikel • Mar 22
Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report
Exagen Inc. ( NASDAQ:XGN ) just released its latest yearly results and things are looking bullish. Exagen beat...Analyse-artikel • Jul 21
Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry
With a price-to-sales (or "P/S") ratio of 0.9x Exagen Inc. ( NASDAQ:XGN ) may be sending very bullish signals at the...Seeking Alpha • Oct 17
Exagen appoints John Aballi as CEO
Exagen (NASDAQ:XGN) has appointed John Aballi as CEO and President. Longtime CEO and President Ron Rocca, who took the company public and built a robust growth business, is stepping down after 11 years at the helm. Most recently, John Aballi served as SVP, General Manager, Urology & CLIA COO at Veracyte.Rendement voor aandeelhouders
| XGN | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 12.7% | 6.2% | -0.8% |
| 1Y | -24.5% | 46.3% | 20.5% |
Rendement versus industrie: XGN presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 46.3 % opleverde.
Rendement versus markt: XGN presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 20.5 % opleverde.
Prijsvolatiliteit
| XGN volatility | |
|---|---|
| XGN Average Weekly Movement | 15.3% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: De aandelenkoers van XGN is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 15% ) van XGN is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2002 | 218 | John Aballi | www.exagen.com |
Exagen Inc. ontwerpt, ontwikkelt en verkoopt verschillende testproducten onder de merknaam AVISE in de Verenigde Staten. Het bedrijf stelt zorgverleners in staat om voor patiënten te zorgen door middel van diagnose, prognose en monitoring van complexe reumatische, auto-immuun- en auto-immuungerelateerde ziekten, waaronder systemische lupus erythematosus (SLE) en reumatoïde artritis (RA). Het belangrijkste testproduct van het bedrijf is AVISE CTD dat een differentiële diagnose mogelijk maakt voor patiënten die symptomen vertonen die wijzen op verschillende bindweefselziekten (CTD's) en andere verwante ziekten met overlappende symptomen.
Exagen Inc. Samenvatting
| XGN fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$159.64m |
| Inkomsten(TTM) | -US$18.92m |
| Inkomsten(TTM) | US$71.12m |
2.5x
P/S-verhouding-9.5x
Koers/WinstverhoudingIs XGN overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| XGN resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$71.12m |
| Kosten van inkomsten | US$29.42m |
| Brutowinst | US$41.70m |
| Overige uitgaven | US$60.63m |
| Inkomsten | -US$18.92m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.78 |
| Brutomarge | 58.64% |
| Nettowinstmarge | -26.61% |
| Schuld/Eigen Vermogen Verhouding | 187.0% |
Hoe presteerde XGN op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/19 17:53 |
| Aandelenkoers aan het einde van de dag | 2026/08/19 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Exagen Inc. wordt gevolgd door 8 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |